Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients

Clinical Biochemistry

Volumn 39, Issue 7, 2006, Pages 732-738

  Salm, Paul ^a   Warnholtz, Christopher ^a   Boyd, Jared ^b   Arabshahi, Lili ^b   Marbach, Peter ^c   Taylor, Paul J ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Seradyn   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Everolimus; FPIA; HPLC mass spectrometry; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; PREDNISONE;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REGRESSION ANALYSIS; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS REACTIONS; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; SIROLIMUS;

EID: 33745855121     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.03.019     Document Type: Article

References (29)

1. Neumayer H.H., Paradis K., Korn A., et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48 (1999) 694-703
2. Levy G.A., Grant D., Paradis K., Campestrini J., Smith T., and Kovarik J.M. Pharmacokinetics and tolerability of 40-O-(2-hydroxyethyl)rapamycin in de novo liver transplant recipients. Transplantation 71 (2001) 160-163
3. Kahan B.D., Kaplan B., Lorber M.I., Winkler M., Cambon N., and Boger R.S. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 71 (2001) 1400-1406
4. Vidal C., Kirchner G.I., and Sewing K.F. Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. J Am Soc Mass Spectrom 9 (1998) 1267-1274
5. Kirchner G.I., Walker M., Mueller L., et al. Pharmacokinetics of SDZ RAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 50 (2000) 449-454
6. Jacobsen W., Serkova N., Hausen B., Morris R.E., Benet L.Z., and Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 33 (2001) 514-515
7. Spatzenegger M., and Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27 (1995) 397-417
8. Budde K., Neumayer H.H., Lehne G., et al. Tolerability and steady state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 19 (2004) 2606-2614
9. Kovarik J.M., Tedesco H., Pascual J., et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 26 (2004) 499-505
10. Baldelli S., Murgia S., Merlini S., et al. High-performance liquid chromatography with ultra-violet detection for therapeutic drug monitoring of everolimus. J Chromatogr B Biomed Sci Appl 816 (2005) 99-105
11. Boudennaia T.Y., and Napoli K.L. Validation of a practical liquid chromatography with ultra violet detection method for quantification of whole blood everolimus in a clinical TDM laboratory. Ther Drug Monit 27 (2005) 171-177
12. Segarra I., Brazelton T.R., Guterman N., et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl 720 (1998) 179-187
13. Vidal C., Kirchner G.I., Wünsch G., and Sewing K.F. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin Chem 44 (1998) 1275-1282
14. Kirchner G.I., Vidal C., Winkler M., et al. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood. Ther Drug Monit 21 (1999) 116-122
15. Christians U., Jacobsen W., Serkova N., et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 748 (2000) 41-53
16. McMahon L.M., Luo S., Hayes M., and Tse F.L. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96 well solid-phase extraction system. Rapid Commun Mass Spectrom 14 (2000) 1965-1971
17. Brignol N., McMahon L.M., Luo S., and Tse F.L. High-throughput semi-automated 96 well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD0001) and cyclosporin A (CsA) in whole blood. Rapid Commun Mass Spectrom 15 (2001) 898-907
18. Streit F., Armstrong V.W., and Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporine A in whole blood. Clin Chem 48 (2002) 955-958
19. Salm P., Taylor P.J., Lynch S.V., and Pillans P.I. Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 772 (2002) 283-290
20. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
21. Innofluor® Certican® Assay System (revision 12/03) [Product Insert]. Seradyn Inc, IN, 2003.
22. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i (1986) 307-310
23. Shah V.P., Midha K.K., Findlay J.W., et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 17 (2000) 1551-1557
24. Bowers L.D. Analytical goals in therapeutic drug monitoring. Clin Chem 44 (1998) 375-380
25. Shaw L.M., Annesley T.M., Kaplan B., and Brayman K.L. Analytical requirements for immunosuppresive drugs in clinical trials. Ther Drug Monit 17 (1995) 577-583
26. Taylor P.J. Therapeutic drug monitoring of immunosuppressant drugs by HPLC-mass spectrometry. Ther Drug Monit 26 (2004) 215-219
27. Engelmayer J., Engelmayer U., Streit F., et al. Comparison of the Seradyn Innofluor® Certican® assay on TDxFLx® system with LC/MS-MS [Abstract]. Ther Drug Monit 27 (2005) 217
28. Cogill J.L., Taylor P.J., Westley I.S., Morris R.G., Lynch S.V., and Johnson A.G. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 44 (1998) 1942-1946
29. Salm P., Taylor P.J., and Pillans P.I. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle immunoassay in renal transplant recipients. Clin Ther 22 Suppl. B (2000) B71-B85